Proclara Biosciences Stock

proclarabio.comHealthcareFounded: 2006Funding to Date: $112.79MM

Developer of disease-modifying therapies intended to be used for the treatment of neurodegenerative diseases. The company's therapies develop novel therapies that recognize and target multiple misfolded proteins, enabling clinicians to make a transformative impact on the lives of patients affected by Alzheimer's, Parkinson's and systemic amyloidosis.

Register for Details

For more details on financing and valuation for Proclara Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Proclara Biosciences.

Register Today

Team

Management Team

Hampus Hillerstrom
Executive Vice President, Co-Founder & Chief Financial Officer
David Michelson MD
Chief Medical Officer & Board Member
Beka Solomon Ph.D
Scientific Founder & Member, Scientific Advisory Board
Jonathan Solomon
Co-Founder and Board Member
Richard Fisher
Chief Executive Officer, President & Board Member

Board Members

David Michelson MD
Jonathan Solomon
Nick Leschly
Paul Goldenheim MD
Valérie Calenda Ph.D
Mérieux Développement
François Valencony
Mérieux Développement
Franz Hefti Ph.D
Kenneth Buckfire
Peter Smedvig
Saira Ramasastry
Daniel Lynch
Hans Schoepflin
Beka Solomon Ph.D
Nico Dosenbach Ph.D
Richard Fisher
Vicki Sato Ph.D

Other companies like Proclara Biosciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$1.08B
Sector
 
 

News

Proclara Biosciences, a Cambridge, MA-based biotechnology company developing novel therapies for diseases caused by protein misfolding, secured $47m in Series E financing. The round was led by existing investors including private investors and Merieux Developpement. As part of the Series E financing, Daniel Lynch, an experienced biotechnology executive and a venture partner at Third Rock Ventures, …